Pyomyositis Secondary to Localized Cellulitis in a Dermatomyositis Patient: A Case Report and Review of Infectious Complications in Dermatomyositis

References

• Svensson J, Holmqvist M, Lundberg IE, Arkema EV. Infections and respiratory tract disease as risk factors for idiopathic inflammatory myopathies: a population-based case-control study. Ann Rheum Dis. 2017;76(11):1803–1808. doi:10.1136/annrheumdis-2017-211174
   PubMed Web of Science ®Google Scholar
• Amaral Silva M, Cogollo E, Isenberg DA. Why do patients with myositis die? A retrospective analysis of a single-centre cohort. Clin Exp Rheumatol. 2016;34(5):820–826.
   PubMed Web of Science ®Google Scholar
• Nuño L, Joven B, Carreira P, et al. [Multicenter registry on inflammatory myositis from the Rheumatology Society in Madrid, Spain: descriptive analysis] Registro de pacientes con miopatía inflamatoria de la Sociedad Madrileña de Reumatología: análisis descriptivo. Reumatol Clin. 2017;13(6):331–337. Spanish. doi:10.1016/j.reuma.2016.07.010
   PubMedGoogle Scholar
• Nuño-Nuño L, Joven BE, Carreira PE, et al. Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain. Rheumatol Int. 2017;37(11):1853–1861. doi:10.1007/s00296-017-3799-x
   PubMed Web of Science ®Google Scholar
• Taborda AL, Azevedo P, Isenberg DA. Retrospective analysis of the outcome of patients with idiopathic inflammatory myopathy: a long-term follow-up study. Clin Exp Rheumatol. 2014;32(2):188–193.
   PubMed Web of Science ®Google Scholar
• Limaye V, Hakendorf P, Woodman RJ, Blumbergs P, Roberts-Thomson P. Mortality and its predominant causes in a large cohort of patients with biopsy-determined inflammatory myositis. Intern Med J. 2012;42(2):191–198. doi:10.1111/j.1445-5994.2010.02406.x
   PubMed Web of Science ®Google Scholar
• Guimarães F, Yildirim R, Isenberg DA. Long-term survival of patients with idiopathic inflammatory myopathies: anatomy of a single-centre cohort. Clin Exp Rheumatol. 2023;41(2):322–329. doi:10.55563/clinexprheumatol/486yh4
   PubMedGoogle Scholar
• Johnson NE, Arnold WD, Hebert D, et al. Disease course and therapeutic approach in dermatomyositis: a four-center retrospective study of 100 patients. Neuromuscul Disord. 2015;25(8):625–631. doi:10.1016/j.nmd.2015.04.013
   PubMed Web of Science ®Google Scholar
• Truzzi NCC, Hoff LS, Borges IBP, de Souza FHC, Shinjo SK. Clinical manifestations, outcomes, and antibody profile of Brazilian adult patients with dermatomyositis: a single-center longitudinal study. Adv Rheumatol. 2022;62(1):41. doi:10.1186/s42358-022-00276-x
   PubMedGoogle Scholar
• Sartori Vieira C, de Rezende RPV, Mendes Klumb E, Cardoso Mocarzel LO, Altenburg Gismondi R. Mortality profile related to the spectrum of systemic connective tissue diseases: a retrospective, population-based, case-control study. Lupus. 2019;28(12):1498–1500. doi:10.1177/0961203319876993
   PubMed Web of Science ®Google Scholar
• Tani K, Tomioka R, Sato K, et al. Comparison of clinical course of polymyositis and dermatomyositis: a follow-up study in Tokushima University Hospital. J Med Invest. 2007;54(3–4):295–302. doi:10.2152/jmi.54.295
   PubMedGoogle Scholar
• Lao M, Ouyang H, Li N, et al. Clinical characteristics and associated factors for infection and in-hospital mortality in inpatients with polymyositis/dermatomyositis in China: a retrospective study. Infect Drug Resist. 2023;16:289–299. doi:10.2147/idr.S392585
   PubMed Web of Science ®Google Scholar
• Chan SCW, Chung HY, Lau CS, Li PH. Epidemiology, mortality and effectiveness of prophylaxis for Pneumocystis jiroveci pneumonia among rheumatic patients: a territory-wide study. Ann Clin Microbiol Antimicrob. 2021;20(1):78. doi:10.1186/s12941-021-00483-2
   PubMed Web of Science ®Google Scholar
• Naveen R, Rathore U, Agarwal V, Gupta L. Characteristics and outcomes of overlap myositis: a comparative multigroup cohort study in adults from the MyoCite cohort. Rheumatol Int. 2021;41(3):551–563. doi:10.1007/s00296-020-04779-y
   PubMed Web of Science ®Google Scholar
• Bae S, Charles-Schoeman C. Oral cyclophosphamide in treatment of patients with refractory idiopathic inflammatory myopathies: a retrospective observational study. Clin Rheumatol. 2018;37(8):2113–2123. doi:10.1007/s10067-018-4174-3
   PubMed Web of Science ®Google Scholar
• Redondo-Benito A, Curran A, Villar-Gomez A, et al. Opportunistic infections in patients with idiopathic inflammatory myopathies. Int J Rheum Dis. 2018;21(2):487–496. doi:10.1111/1756-185x.13255
   PubMed Web of Science ®Google Scholar
• Xiao Y, Luo H, Zhou B, et al. Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy. Rheumatol Int. 2017;37(4):585–592. doi:10.1007/s00296-016-3609-x
   PubMed Web of Science ®Google Scholar
• Couderc M, Gottenberg JE, Mariette X, et al. Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. Rheumatology. 2011;50(12):2283–2289. doi:10.1093/rheumatology/ker305
   PubMed Web of Science ®Google Scholar
• Conticini E, d’Alessandro M, Grazzini S, et al. Rituximab-induced hypogammaglobulinaemia in patients affected by idiopathic inflammatory myopathies: a multicentre study. Clin Exp Rheumatol. 2023;41(2):285–290. doi:10.55563/clinexprheumatol/790ihy
   PubMed Web of Science ®Google Scholar
• Cronin ME, Miller FW, Hicks JE, Dalakas M, Plotz PH. The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. J Rheumatol. 1989;16(9):1225–1228.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, García-Hernández FJ, de Ramón E, et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol. 2010;28(4):468–476.
   PubMed Web of Science ®Google Scholar
• Cheng L, Li Y, Wu Y, et al. Risk of early infection in idiopathic inflammatory myopathies: cluster analysis based on clinical features and biomarkers. Inflammation. 2023;46:1036–1046. doi:10.1007/s10753-023-01790-w
   PubMed Web of Science ®Google Scholar
• Nuño-Nuño L, Joven BE, Carreira PE, et al. Overlap myositis, a distinct entity beyond primary inflammatory myositis: a retrospective analysis of a large cohort from the REMICAM registry. Int J Rheum Dis. 2019;22(8):1393–1401. doi:10.1111/1756-185x.13559
   PubMed Web of Science ®Google Scholar
• Rouster-Stevens KA, Morgan GA, Wang D, Pachman LM. Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res. 2010;62(10):1446–1451. doi:10.1002/acr.20269
   PubMed Web of Science ®Google Scholar
• Prasad S, Misra R, Agarwal V, Lawrence A, Aggarwal A. Juvenile dermatomyositis at a tertiary care hospital: is there any change in the last decade? Int J Rheum Dis. 2013;16(5):556–560. doi:10.1111/1756-185x.12053
   PubMed Web of Science ®Google Scholar
• Ruperto N, Pistorio A, Oliveira S, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016;387(10019):671–678. doi:10.1016/s0140-6736(15)01021-1
   PubMed Web of Science ®Google Scholar
• Bader-Meunier B, Decaluwe H, Barnerias C, et al. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. J Rheumatol. 2011;38(7):1436–1440. doi:10.3899/jrheum.101321
   PubMed Web of Science ®Google Scholar
• Uchino M, Yamashita S, Uchino K, et al. Long-term outcome of polymyositis treated with high single-dose alternate-day prednisolone therapy. Eur Neurol. 2012;68(2):117–121. doi:10.1159/000338474
   PubMed Web of Science ®Google Scholar
• Hsu CY, Ko CH, Wang JL, Hsu TC, Lin CY. Comparing the burdens of opportunistic infections among patients with systemic rheumatic diseases: a nationally representative cohort study. Arthritis Res Ther. 2019;21(1):211. doi:10.1186/s13075-019-1997-5
   PubMed Web of Science ®Google Scholar
• Cherin P, Piette JC, Wechsler B, et al. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. J Rheumatol. 1994;21(6):1092–1097.
   PubMed Web of Science ®Google Scholar
• Unger L, Kampf S, Lüthke K, Aringer M. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. Rheumatology. 2014;53(9):1630–1638. doi:10.1093/rheumatology/keu024
   PubMed Web of Science ®Google Scholar
• Takada K, Katada Y, Ito S, et al. Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis/dermatomyositis: a single-arm clinical trial. Rheumatology. 2020;59(5):1084–1093. doi:10.1093/rheumatology/kez394
   PubMed Web of Science ®Google Scholar
• Tillie-Leblond I, Wislez M, Valeyre D, et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax. 2008;63(1):53–59. doi:10.1136/thx.2006.069237
   PubMed Web of Science ®Google Scholar
• Tsuji H, Nakashima R, Hosono Y, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol. 2020;72(3):488–498. doi:10.1002/art.41105
   PubMed Web of Science ®Google Scholar
• Shirai T, Machiyama T, Sato H, Ishii T, Fujii H. Intensive induction therapy combining tofacitinib, rituximab and plasma exchange in severe anti-melanoma differentiation-associated protein-5 antibody-positive dermatomyositis. Clin Exp Rheumatol. 2023;41(2):291–300. doi:10.55563/clinexprheumatol/8kulbf
   PubMed Web of Science ®Google Scholar
• Billet AC, Barba T, Coutant F, et al. Infection risk in patients with dermatomyositis associated with anti-MDA5 antibodies: a historical cohort study. Biomedicines. 2022;10(12). doi:10.3390/biomedicines10123176
   PubMed Web of Science ®Google Scholar
• Matsuda KM, Yoshizaki A, Kuzumi A, et al. Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis. J Dermatol. 2020;47(5):483–489. doi:10.1111/1346-8138.15274
   PubMed Web of Science ®Google Scholar
• Tsai SY, Lin CL, Wong YC, et al. Increased risk of herpes zoster following dermatomyositis and polymyositis: a nationwide population-based cohort study. Medicine. 2015;94(28):e1138. doi:10.1097/md.0000000000001138
   PubMed Web of Science ®Google Scholar
• Liu L, Zhang Y, Liu S, et al. Compound sulfamethoxazole improved the prognosis of dermatomyositis patients positive with anti-melanoma differentiation-associated gene 5. Rheumatology. 2023. doi:10.1093/rheumatology/kead034
   Google Scholar
• Li J, Wang S, Zheng J, Li Q, Li J, Lu L. Clinical characteristics of and risk factors for Pneumocystis jirovecii pneumonia in anti-melanoma differentiation-associated gene 5 (Anti-MDA5) antibody-positive dermatomyositis patients: a single-center retrospective study. Clin Rheumatol. 2023;42(2):453–462. doi:10.1007/s10067-022-06403-9
   PubMed Web of Science ®Google Scholar